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Abstract
Background—Consensus guidelines recommend that adults at low risk for group A 
streptococcal (GAS) pharyngitis be neither tested nor treated
Objective—To help patients decide when to visit a clinician for the evaluation of sore throat.
Design—Retrospective cohort study.
Setting—A national chain of retail health clinics.
Patients—71 776 patients aged 15 years or older with pharyngitis who visited a clinic from 
September 2006 to December 2008.
Measurements—The authors created a score using information from patient-reported clinical 
variables plus the incidence of local disease and compared it with the Centor score and other 
traditional scores that require clinician-elicited signs.
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Results—If patients aged 15 years or older with sore throat did not visit a clinician when the new 
score estimated the likelihood of GAS pharyngitis to be less than 10% instead of having clinicians 
manage their symptoms following guidelines that use the Centor score, 230 000 visits would be 
avoided in the United States each year and 8500 patients with GAS pharyngitis who would have 
received antibiotics would not be treated with them.
Limitation—Real-time information about the local incidence of GAS pharyngitis, which is 
necessary to calculate the new score, is not currently available.
Conclusion—A patient-driven approach to pharyngitis diagnosis that uses this new score could 
save hundreds of thousands of visits annually by identifying patients at home who are unlikely to 
require testing or treatment.
Primary Funding Source—Centers for Disease Control and Prevention and the National 
Library of Medicine, National Institutes of Health.
Globally, group A streptococcal (GAS) pharyngitis affects hundreds of millions of persons 
each year (1, 2). In the United States, more than 12 million persons make outpatient visits 
for pharyngitis; however, clinicians cannot differentiate GAS pharyngitis from other causes 
of acute pharyngitis (for example, viral) on the basis of a physical examination of the 
oropharynx (3).
The American College of Physicians and Centers for Disease Control and Prevention 
recommend that health care providers apply clinical scores to classify risk for GAS 
pharyngitis and direct management of adults with acute pharyngitis (Table 1) (4–6). When 
the clinical score indicates a low risk, consensus guidelines recommend that adult patients 
should be neither tested nor treated for GAS pharyngitis. The updated 2012 guidelines from 
the Infectious Diseases Society of America concur that clinical scoring systems may help 
identify patients with pharyngitis at sufficiently low risk for GAS pharyngitis that testing 
may not be necessary (7).
We recently showed that the contemporaneous local incidence of GAS pharyngitis is an 
important predictor of this condition among patients presenting with a sore throat to CVS 
MinuteClinics, a large chain of retail health clinics where data are captured uniformly in a 
single electronic health record (8). Building on this framework, we derived a disease 
prediction model that we call the “home score” because it was designed for use at home by 
the patient without input from a clinician and relies on the patient to provide historical 
features but not physical examination findings (Table 1). The model also includes a local 
incidence variable for streptococcus, bringing biosurveillance data into the clinical process. 
We seek to evaluate whether this participatory medicine approach could reduce unnecessary 
outpatient and emergency department visits for pharyngitis not requiring antibiotic 
treatment.
Methods
Study Design
We retrospectively analyzed a cohort of patients tested for GAS pharyngitis when they 
presented with a sore throat from 1 September 2006 to 1 December 2008 to CVS 
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MinuteClinics, which has about 600 sites in 25 states and the District of Columbia (9–13). 
MinuteClinics provide care for patients with a limited number of conditions, including sore 
throat. This data set included 238 656 patient encounters where physician assistants or nurse 
practitioners collected standardized information from the history and physical examination 
based on algorithm-driven care. Clinicians enter codified data in real time, and the records 
are stored in a common database.
MinuteClinic providers have shown more than 99% adherence to a recognized protocol for 
acute pharyngitis: the Strep Pharyngitis Algorithm from the Institute for Clinical Systems 
Improvement (14, 15). Guided by the algorithm, clinicians collect structured information 
about relevant signs and symptoms, acquire rapid testing on all patients with pharyngitis, 
ordering confirmatory testing when the rapid test results are negative), and treat only 
patients with positive test results for GAS pharyngitis. All visits in this data set contained 
complete information about age; all signs and symptoms included in 2 traditional, validated 
clinical scores (the Centor and McIsaac scores); and test results (Table 1) (4, 16).
Our study included patients with a chief symptom of sore throat or symptoms of pharyngitis 
with testing performed for GAS pharyngitis. Patients who reported having been treated for 
GAS pharyngitis within the previous month and those younger than 15 years were excluded. 
When patients contributed more than 1 visit to the data set, only the first visit was included. 
MinuteClinic policy is to care only for patients who are generally well-appearing; those with 
concern for sepsis are referred to emergent care centers.
Test Methods
All clinic locations used the QuickVue In-Line Strep A test (Quidel, San Diego, California), 
which was waived under the Clinical Laboratory Improvement Amendments. The 
confirmatory test was a throat culture (43%) or streptococcal DNA probe (57%), which is 
often considered equal to culture and is widely used in the United States (17, 18). Patients 
were categorized as positive for GAS pharyngitis if the rapid or confirmatory test results 
were positive.
Statistical Analysis
The analysis was restricted to 9 MinuteClinic markets from 6 states (Georgia, Indiana, 
Maryland, Minnesota, North Carolina, and Tennessee) with a minimum of 7000 patient 
visits each for pharyngitis during the study. Two thirds of the patients were selected 
randomly for derivation and the rest for validation. We repeated all steps used on the 
derivation set with the validation set to compare results. To enable integration of 
contemporaneous, local epidemiologic data on GAS pharyngitis, we used a previously 
validated biosurveillance variable reflecting disease incidence, the recent local proportion 
positive (RLPP) (8), expressed using the following equation (Appendix, available at 
www.annals.org).
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The RLPP was assigned for each patient visit on the basis of location and date.
Variable Selection
Our a priori hypothesis was that the original variables from the Centor and McIsaac scores 
would dominate the home score. Because the purpose of the home score is to focus on 
information that can be supplied by the patient combined with biosurveillance-derived 
knowledge, we excluded physical examination variables (tender anterior cervical lymph 
nodes and exudates) from the Centor and McIsaac scores and added the RLPP variable. A 
stepwise selection model with 15 home score predictors (sex, absence of cough, pain when 
swallowing, history of fever, exposure to GAS pharyngitis, stomachache, difficulty sleeping, 
ear pain, postnasal discharge, hoarseness, headache, nausea, vomiting, and lack of 
rhinorrhea confirmed the hypothesis, identifying the same home variables from the original 
Centor and McIsaac scores (fever, absence of cough, and age) and RLPP.
Home Score Calculation
The home score (range, 8–62) is based on demographic, historical, and biosurveillance data 
only, not physical examination data. To calculate the home score for each patient, we used 
the results of logistic regression based on the final model to calculate the predicted 
probability (0–100) of GAS pharyngitis. The home score can be calculated from the 
following equation, where f = −1 if fever is present, f = 1 if fever is not present, c = 1 if 
cough is present, and c = −1 if cough is not present.
For example, for a 41-year-old patient with fever and cough who presented when the RLPP 
was 0.19, the home score would be 23.
For each home score of 0 to 100, we calculated the percentage of patients who actually 
tested positive for GAS pharyngitis and examined the relationship between the home score 
and positivity for GAS pharyngitis. Standard metrics (sensitivity, specificity, and positive 
and negative predictive values) compared performance of the home score with the Centor 
and McIsaac scores and the clinical biosurveillance score (Table 1) (8). The Centor and 
McIsaac scores rely on elements derived from the history and physical examination. To 
calculate the Centor score, patients receive 1 point for each of the following factors: fever; 
absence of cough; presence of tonsillar exudates; and swollen, tender anterior cervical 
lymph nodes. The Centor score is the sum of these points (range, 0–4).
The McIsaac score (range, 0–5) adjusts the Centor score to account for the increased 
incidence of GAS pharyngitis in children and decreased incidence in older adults by adding 
1 point to the Centor score for those younger than 15 years and subtracting 1 point for those 
aged 45 years or older. The clinical biosurveillance score (range, 4–79) adjusts the Centor 
score on the basis of real-time biosurveillance data about the recent local incidence of GAS 
pharyngitis (Appendix). We calculated the clinical biosurveillance score by adjusting a 
Fine et al. Page 4
Ann Intern Med. Author manuscript; available in PMC 2014 May 05.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
patient’s Centor score with the RLPP by using the equations in the Appendix Table 
(available at www.annals.org).
Hypothetical Outcomes
We computed the number of patients who, according to the home score, were at low risk for 
GAS pharyngitis and therefore might avoid or delay a trip to a medical provider. The 
Centers for Disease Control and Prevention advocates the American College of Physicians 
guideline based on the Centor score for management of acute pharyngitis in adults. This 
guideline recommends that adult patients who are unlikely to have GAS pharyngitis (Centor 
score, 0–1) should be neither tested nor treated (5). We calculated the Centor scores for 
these patients as well as the following outcomes: the numbers of visits saved and additional 
missed cases of GAS pharyngitis compared with the existing American College of 
Physicians and Centers for Disease Control and Prevention approach.
Analyses ranged across a spectrum of risk thresholds for GAS pharyngitis. We extrapolated 
results to project the effect on 12 million national visits for pharyngitis annually. We 
tabulated outcomes across a wide range of home score thresholds from 10 to 30. Metrics 
include the number of patients who were correctly and incorrectly diagnosed with GAS 
pharyngitis and the estimated number of patients nationally whose management would be 
affected by the home score.
The Boston Children’s Hospital Committee on Clinical Investigation approved this database 
analysis. JMP Pro software, version 10.0.0 (SAS Institute, Cary, North Carolina), was used 
for statistical analyses.
Role of the Funding Source
This work was supported by the Centers for Disease Control and Prevention and the 
National Library of Medicine, National Institutes of Health. The funding sources had no role 
in the study design, data analysis, data interpretation, writing of the manuscript, or decision 
to submit the manuscript for publication.
Results
Of the 132 821 patient visits to 1 of the 9 locations with at least 7000 patient visits, 6726 
visits from patients treated in the previous month, 39 279 visits from patients younger than 
15 years, and 15 040 repeated visits were excluded, leaving 71 776 visits for calculation of 
the home score (Figure). Of these, two thirds were used for the derivation set (n = 48 089) 
and one third for the validation set (n = 23 687).
Among the 48 089 retail health visits for patients aged 15 years or older in the derivation set, 
11 614 (24%) tested positive for GAS pharyngitis. In the validation set, 5728 of 23 687 
(24%) tested positive. Table 2 shows the characteristics of the derivation and validation sets 
for age, sex, and clinical signs and symptoms of pharyngitis by GAS pharyngitis result for 
those aged 15 years or older. Table 2 also contains information about the epidemiologic 
conditions of GAS pharyngitis (RLPP) when the patient visits took place. In both groups, 
patients who tested positive for GAS pharyngitis were more likely to present with tonsillar 
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exudates, swollen anterior cervical lymph nodes, absence of cough, and fever in the previous 
24 hours. Table 3 shows the sensitivity, specificity, and positive and negative predictive 
values of a range of home score thresholds for the derivation and validation sets.
Home Score Performance
Table 4 shows outcomes of patients when using strategies based on the low-risk thresholds 
where neither testing nor treatment would occur. Two thresholds for the home score and the 
low-risk thresholds for the Centor and McIsaac scores of less than 2 are shown. If the home 
score is less than 10, the negative predictive value is 0.90, which means that 90% of the 
patients identified as low risk by the home score would have tested negative for GAS 
pharyngitis.
Table 5 summarizes the outcomes if patients were managed on the basis of a home score 
determined to be low risk. For example, if the home score were less than 10, for every 
missed patient with GAS pharyngitis, 27 health care visits could be saved in which patients 
would have been neither tested nor treated for GAS pharyngitis. At a national scale, this 
would save 230 000 visits annually. This cutoff also could be expected to miss an additional 
8500 cases annually of GAS pharyngitis compared with a conventional Centor score--based 
approach. However, most patients with GAS pharyngitis have a self-limited course.
Complications from missed cases include acute rheumatic fever, which is rare in adults; 
acute glomerulonephritis that would not be prevented even with antibiotics; and abscess 
formation, highlighting the importance of close follow-up and recognition of patients who 
seem ill. At a higher home score threshold of 15, a total of 61 000 additional patients would 
be missed nationally in 1 year but 780 000 visits would be saved.
Discussion
Clinical prediction models tend to rely on elements gleaned from a patient’s history, 
physical examination, and preliminary laboratory data to calculate the likelihood of disease 
and then provide physicians with recommendations about whether to test or treat patients for 
specific conditions (19–22). Recent, local epidemiology is an important predictor of the risk 
for communicable diseases among symptomatic patients but is rarely if ever integrated 
quantitatively into prediction models (8, 23–25). We have internally validated a fusion 
model using population health data and information supplied directly by patients, using both 
biosurveillance and participatory medicine approaches to make a common diagnostic 
decision The model, based on history and recent, local disease patterns without physical 
examination information, could help clinicians and patients estimate the likelihood of 
disease before a clinical encounter and help steer these patients to timely, appropriate care 
when needed. In some instances, patients unlikely to have GAS pharyngitis might avoid, or 
at least delay, an emergency or outpatient visit.
Anhang Price and colleagues (26) and Kellermann and colleagues (27) have shown the 
feasibility of Web-based triaging by patients and parents of children with influenza-like 
illness. Although their study showed great sensitivity in detecting children at risk for 
complications of influenza, it had low specificity. Our analysis of GAS pharyngitis offers an 
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opportunity for improving specificity via home triage that incorporates clinical symptoms 
with relevant, real-time biosurveillance. One other advantage of a home triage system for 
well-appearing adults with pharyngitis is that acute decompensation is much less probable in 
this population than in children with influenza.
Even without information from physical examination findings, the home score approaches 
the accuracies and overall performances of the existing validated scores. Clinicians could 
use the home score to interact with patients online or over the telephone. There may also be 
circumstances in which it would be safe for patients themselves to be guided by a home 
score application.
For example, a home score less than 10 (low risk) might yield the recommendation of 
supportive measures, such as fever control, rest, and hydration. A tailored message could 
recommend that these patients recheck their home score in 24 to 48 hours. Because the 
home score is dynamic, a change in symptoms or local epidemiology could result in a 
different recommendation.
Patients with higher scores might be advised to seek care for further evaluation and possibly 
testing. Presenting the absolute risk for GAS pharyngitis and the corresponding 
recommendation could decrease ambulatory visits that would have been unlikely to result in 
diagnostic testing for this condition but would have contributed to increased cost, reduced 
efficiency of the health system, and opportunity cost for the patient. An additional public 
health benefit could be reduced antibiotic exposure, lessening selection for drug-resistant 
strains and perturbation of the normal microflora.
Patient-generated data for care and research are becoming increasingly common with further 
penetration of consumer technology and use of patient portals, personally controlled health 
records, and mobile health applications (28–30). Although the GAS pharyngitis home score 
shows the potential value of these data, safe and effective implementation requires key 
logistic and workflow decisions.
First, the strategy requires national, regional, or local approaches to making the 
biosurveillance data available at the point of care. Because so many patients are tested for 
GAS pharyngitis, most hospitals and many large group practices would have sufficient data 
to generate their own RLPPs. Second, implementers can decide whether a computerized 
decision-support system based on patient-entered data advises patients directly or is used to 
guide their providers’ decisions through a shared portal or application.
The home score could help clinicians estimate the risk for GAS pharyngitis in children. 
However, because the American Academy of Pediatrics recommends that all pediatric 
patients with pharyngitis be tested for GAS pharyngitis, we did not include children younger 
than 15 years in the analyses about visits saved.
Our study has limitations. Analyses were performed retrospectively, although all data were 
collected prospectively. Data are not available to calculate interobserver agreement or 
reliability. Patients entering their symptoms at home could answer differently during a 
MinuteClinic encounter. These data do not reflect the incidence of other pathogens that can 
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cause pharyngitis, such as Fusobacterium necrophorum, which may be particularly severe in 
young adults and adolescents and is one pathogen that may cause the Lemierre syndrome 
(31).
Our data do not allow evaluation of streptococcal carriage, although all patients in this data 
set were symptomatic with a sore throat; thus, those testing positive would be treated 
clinically. Performance of the score in a home setting would be best if the patients 
resembled the MinuteClinic clientele who were included in this study. We recommend that 
any application using the home score limit it to patients without signs or symptoms of 
serious illness.
We cannot account for baseline immunity to GAS pharyngitis within the population nor the 
local emergence of hypervirulent GAS pharyngitis strains or infectious causes of 
community-acquired pharyngitis, which may vary across regions. Data more recent than 
2008 were not available for analysis, but the approach to patients with pharyngitis by 
MinuteClinics has not changed. The same electronic medical record, algorithm-driven 
approach, and testing methods are still used, with consistently high provider adherence to 
protocol. One possible limitation is that the prevalence of GAS pharyngitis among 
MinuteClinic patients could have changed over time, although one generalizable strength of 
our model is that it considers a range of prevalence of GAS pharyngitis.
Logistically, integration of a home score might result in lower testing rates by providers, 
which could weaken the RLPP as a reliable surveillance indicator; therefore, it would be 
necessary to maintain testing on an intentional sample of patients each week to account for 
this. The RLPP, as a surveillance variable, is a trailing indicator, so the accuracy of the 
home score could decrease if GAS pharyngitis rates rapidly changed. To mitigate this effect, 
we used a 14-day RLPP rather than a 3- or 7-day RLPP, all of which had similar accuracy in 
the study population.
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Appendix: Calculation of the RLPP and the Clinical Biosurveillance Score
Calculation of the RLPP
The RLPP is a biosurveillance variable that we created previously to reflect the real-time 
epidemiology of GAS pharyngitis. To calculate the RLPP, we included test results from the 
study population as well as from younger patients. We included data from patients younger 
than 15 years when calculating the overall local incidence data because they contribute to 
the epidemiologic context of the clinically analyzed population. The RLPP is a moving 
window.
To calculate the 14-day RLPP for a patient seen on 15 January 2007, for example, we 
divided the number of positive GAS pharyngitis test results by the number of tests sent in 
that market from 1 to 14 January 2007. We calculated 3-, 7-, and 14-day RLPPs and 
compared them using the Pearson correlation coefficients. The 3-, 7-, and 14-day RLPPs 
were strongly correlated (14 vs. 7: r2= 0.79 [P < 0.001]; 7 vs. 3: r2 = 0.63 [P < 0.001]; and 
14 vs. 3: r2 = 0.48 [P < 0.001]), so we used the 14-day RLPP for subsequent analyses 
because it provides a realistic time frame to generate reliable, contemporaneous local data 
on GAS pharyngitis.
In the derivation set, an individual patient’s 14-day RLPP was calculated on the basis of a 
mean of 227 patients (SD, 115; 95% CI, 226 to 228; median, 198 patients [interquartile 
range, 132 to 334]) tested in that area in the previous 14 days. The median RLPP was 0.25 
(interquartile range, 0.20 to 0.30; overall range, 0.08 to 0.51). The RLPP substantially 
fluctuated across time and location (8).
Calculation of the Clinical Biosurveillance Score
The clinical biosurveillance score can be calculated by adjusting a patient’s Centor score on 
the basis of the RLPP, as defined by the equations in the Appendix Table(8). For example, 
for a patient with a Centor score of 2 who presents when the RLPP is 0.33, the clinical 
biosurveillance score would be 8.8 + 64 * (0.33), which equals 30.
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Figure 1. 
Patient flow diagram
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